Optimization of Clinical Treatment Schemes for Multidrug - resistant Pulmonary Tuberculosis Based on Host - mediate

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-16009545

Enrollment

Unknown

Registered

2016-10-21

Start date

2016-10-21

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multi drug resistant pulmonary tuberculosis

Interventions

Zyflo interference group:Chemotherapy + Zyflo stay through

Non-interfering group control group:Chemotherapy alone

Eligibility

Sex/Gender

All

Age

3 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years old; 2. No serious heart, liver, kidney, brain disease; 3. No diabetes; 4. No mental illness, good compliance; 5. No merger of HIV; 6. lesions were confined or diffuse, unilateral or bilateral changes; 7. Two or more than two kinds of anti-TB drug resistance; 8. sputum positive; 9. Provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergic to leukotriene inhibitors; 2. Can not tolerate Zyflo stay through; 3. Taking part in other clinical trials; 5. With a history of asthma in the attack; 6. Complicated with severe liver, kidney, brain, heart disease; 7. For various reasons can not complete the course of treatment; 8. Irresistible factors.

Design outcomes

Primary

Measure	Time frame
COX-2;IL-1Ra;IFN-ß;IFN-a;	—

Countries

China

Contacts

Public ContactYanzheng Song

Shanghai Public Health Clinical Center

yanzhengsong@163.com+86 18930360891

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026